De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NuVasive Toekomstige groei

Future criteriumcontroles 3/6

NuVasive zal naar verwachting groeien in winst en omzet met respectievelijk 46.2% en 6.7% per jaar. De winst per aandeel zal naar verwachting groeien met 44.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 14.3% zijn.

Belangrijke informatie

46.2%

Groei van de winst

44.6%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.5%
Inkomstengroei	6.7%
Toekomstig rendement op eigen vermogen	14.3%
Dekking van analisten	Good
Laatst bijgewerkt	01 Sep 2023

Recente toekomstige groei-updates

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05

Winst- en omzetgroeiprognoses

NasdaqGS:NUVA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	1,452	91	114	289	8
12/31/2024	1,360	73	107	233	12
12/31/2023	1,279	38	63	214	12
6/30/2023	1,226	28	-3	140	N/A
3/31/2023	1,219	20	23	165	N/A
12/31/2022	1,202	40	30	169	N/A
9/30/2022	1,199	-20	27	160	N/A
6/30/2022	1,174	-40	44	171	N/A
3/31/2022	1,159	-37	38	157	N/A
12/31/2021	1,139	-64	70	182	N/A
9/30/2021	1,129	-26	103	217	N/A
6/30/2021	1,153	2	122	232	N/A
3/31/2021	1,062	-50	107	212	N/A
12/31/2020	1,051	-37	76	186	N/A
9/30/2020	1,069	-9	78	188	N/A
6/30/2020	1,065	-4	62	175	N/A
3/31/2020	1,153	61	96	216	N/A
12/31/2019	1,168	65	105	235	N/A
9/30/2019	1,146	48	104	229	N/A
6/30/2019	1,127	52	115	235	N/A
3/31/2019	1,116	49	89	207	N/A
12/31/2018	1,102	12	110	219	N/A
9/30/2018	1,085	24	109	209	N/A
6/30/2018	1,060	41	84	187	N/A
3/31/2018	1,038	42	77	185	N/A
12/31/2017	1,027	82	64	177	N/A
9/30/2017	1,027	64	65	179	N/A
6/30/2017	1,019	35	17	123	N/A
3/31/2017	996	53	N/A	127	N/A
12/31/2016	962	37	N/A	158	N/A
9/30/2016	906	42	N/A	137	N/A
6/30/2016	867	51	N/A	154	N/A
3/31/2016	834	31	N/A	120	N/A
12/31/2015	811	66	N/A	89	N/A
9/30/2015	800	62	N/A	67	N/A
6/30/2015	790	47	N/A	102	N/A
3/31/2015	777	33	N/A	118	N/A
12/31/2014	762	-17	N/A	116	N/A
9/30/2014	749	-18	N/A	124	N/A
6/30/2014	728	-9	N/A	113	N/A
3/31/2014	703	-11	N/A	97	N/A
12/31/2013	685	8	N/A	97	N/A
9/30/2013	660	-1	N/A	101	N/A
6/30/2013	639	-6	N/A	97	N/A
3/31/2013	628	3	N/A	114	N/A
12/31/2012	620	3	N/A	130	N/A
9/30/2012	605	-4	N/A	109	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NUVA ( 46.2% per jaar) ligt boven de spaarquote ( 2.2% ).

Winst versus markt: De winst van NUVA ( 46.2% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van NUVA zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van NUVA ( 6.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van NUVA ( 6.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NUVA zal naar verwachting over 3 jaar laag zijn ( 14.3 %).

NuVasive Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 19%

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. Provides Sales Guidance for the Year 2023

Price target decreased to US$49.25

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

Price target decreased to US$56.00

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

CEO & Director exercised options and sold US$708k worth of stock

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.12 profit in 3Q 2020)

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Senior VP & Chief Human Resources Officer Lucas Vitale has left the company

NuVasive, Inc. Simplify Cervical Disc Data Publishes in International Journal of Spine Surgery

Key Executive exercised options and sold US$77k worth of stock

High number of new directors

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?